Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features

Trial Profile

A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2018 Planned End Date changed from 24 Aug 2018 to 24 Aug 2019.
    • 02 Oct 2018 Planned primary completion date changed from 24 Aug 2018 to 24 Aug 2019.
    • 28 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 24 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top